The life sciences sector has learned to publish with scientific authority. It has not yet learned to convert that authority into pipeline — or to make it visible to the engines now shaping how buyers search.
~2,000
companies analysed
1,000
marketing job posts
8
maturity dimensions
H1 2026
collection window
Life sciences marketing is rich in credibility and craft — strong positioning, real expertise, well-maintained, evidence-backed content — and poor in conversion and distribution.
The content is created, often created well, but rarely connected to a buyer journey, rarely distributed, and increasingly invisible to AI search. Across five independent lenses the same pattern recurs: an excellent top of funnel and a missing bottom of one.
We use content marketing broadly — a press release, a webinar, a sales one-pager, a LinkedIn ad and a pillar guide are all content doing a marketing job. Treating them as one system is the only way to see the gaps below.
The closing argument
The hard, expensive part — authority — is largely solved. The cheaper, higher-leverage part — connecting it to pipeline — is wide open.
The companies that close that gap won't be the ones that publish the most. They'll be the ones that operationalise what they already make into pipeline the rest of the sector is leaving on the table.
A synthesis of original analysis covering roughly 2,000 life sciences companies — biotech, pharma, MedTech, diagnostics, and the research-services firms (CROs and CDMOs) that supply them — together with 1,000 marketing job postings, all collected in H1 2026. We state totals once and then speak in proportions for the rest of the report.
Maturity audit
Source: Biotech · Pharma · MedTech · Diagnostics · CROs/CDMOs
Every website classified by content presence — active, minimal, or brochure — then scored on eight maturity dimensions for the active cohort.
Visibility & demand
Source: SEO · LinkedIn ads · AI-search probe · tech stack
Ranking-keyword mix, paid-media adoption, AI Overview presence, and infrastructure depth. The base for Part IV — visibility and demand.
Hiring signal
Source: Across biotech, pharma, MedTech, diagnostics, CROs
A budget-backed read on where the operating model is going. Competencies, channels, AI posture — and the two distinct models hidden inside one industry label.
Method note
Source: Directional figures flagged inline
Proportions and ratios — not raw counts pulled from sub-samples. Findings on smaller representative samples or modelled estimates are marked directional in the text.
On directional figures
Where a finding rests on a smaller representative sample or a modelled estimate, it is marked directional. We include them because the direction is more useful to a decision-maker than silence.
Two questions, separated
We carefully separate two questions usually blurred together: does a company do content marketing, and how well does it do it. Unless noted, the analysis follows the active cohort.
Hover or tap each finding to see the underlying numbers and the strategic read.
Finding 01 of 07
~1 in 2
have effectively opted out of content
Only ~48% of life sciences companies maintain an active content presence. ~30% show minimal/incidental signals; ~22% none at all. Activity tracks with headcount and funding stage — and counter-intuitively dips after IPO, when corporate-comms oversight rises and conservatism sets in.
Before maturity, the binary question: is there a content program here at all? For a large share of the sector, the honest answer is no.
Recurring educational material, a resource hub, clear targeting.
A thin, stale blog; a 'news' page that stopped updating.
Brochure-only — operating almost entirely as a digital product brochure.
Just under half of life sciences companies maintain an active content presence: recurring educational material, a resource hub, clear targeting. That is the cohort this report spends most of its time inside.
But it is only half the room. Combine the minimal and brochure-only cohorts and a slim majority of the sector has effectively opted out of content as a demand lever. The brochure majority drags down sector-wide averages; the active cohort is where the instructive variation lives.
For the brochure cohort
Stand up an inbound content engine →
Active content presence, by company stage — directional
Late-stage venture companies show the highest rate of active content marketing. Then, counter-intuitively, the rate falls after IPO — to roughly 1 in 3. Content becomes more conservative as corporate-communications oversight increases.
The growth-stage band — scaling biotech, mid-market device and diagnostics — is simultaneously the most active and the most winnable. Large enough to have a budget; rarely large enough to have a mature, governed content operation.
Why this matters
The growth-stage window — before post-IPO conservatism sets in — is when content operations are both most capable and most willing to convert. That is the sweet spot this entire report keeps circling back to.
The content that exists is real, technical and credible. It is also weighted toward telling the market what happened — not toward helping a buyer choose.
Content type prevalence — share of content-active companies
Decision-stage and commercial-evaluation assets — the formats that help a buyer justify a purchase — are nearly absent.
The near-universal asset is news and press releases, present on more than 4 in 5 sites. Technical documentation follows on roughly 7 in 10, thought leadership on two-thirds — a faithful portrait of an industry that runs on scientific validation and announcement cadence.
The deficit appears the moment content has to do commercial work. The pattern is not laziness — it is discomfort. Life sciences companies are entirely comfortable publishing what a product is and what the science says. They are reluctant to publish anything that helps a buyer evaluate and choose.
Estimate how the active and minimally-active cohorts distribute content across the buyer journey and the imbalance is concrete.
Estimated content distribution across the buyer journey — directional
Awareness content accounts for roughly a third of the mix and consideration for a little over a third — nearly seven in ten of all content serving the top and middle of the funnel.
The decision stage gets only about 1 in 5, and post-purchase support barely 1 in 10. The exact stage split is an estimate, but the shape is unambiguous and matches the format data point for point.
The pull quote
The sector has built an excellent top of funnel and a missing bottom of one. Education without evaluation is a library, not a pipeline.
Presence is binary; maturity is graded. Scoring the active cohort across eight dimensions on a 0–4 scale separates the sector's genuine strengths from the places it consistently leaves value on the table.
The next five sections walk dimension by dimension — from the weakest (demand capture, distribution) through navigation and regulatory depth, to the sector's genuine strengths (E-E-A-T and positioning).
Of every dimension measured, demand capture scores lowest — a mean of 1.89 out of 4. Most companies treat content as a broadcast medium: something to be published, not wired to a next step.
CTA sophistication — share of content-active companies
Lead-capture forms exist on roughly 17 in 20 sites — the problem is not the form. It is the absence of a reason and a path.
Only about 1 in 5 change the call based on funnel stage; fewer than 1 in 6 use any progressive logic that recognises a returning visitor. The default move is a hard pivot: an awareness article drops the reader straight into "Request a Demo," skipping the consideration-stage guide that would have earned the meeting.
UX friction is genuinely low (1.34/4). The sites aren't broken. The friction isn't technical — it's the absence of a compelling commercial pathway.
The opportunity hidden in the gap
Because friction is already low, conversion gains here don't require a redesign — they require architecture: matching the ask to the funnel stage, adding the missing consideration-stage asset between blog and demo, and giving every page one obvious next step. This is the cheapest pipeline most life sciences teams aren't capturing.
Findability scores a middling 2.35 out of 4. The migration from chronological blog feeds to organised resource hubs is well underway — but the details that serve a time-poor reader are missing.
Navigation & blog architecture — feature prevalence
Key takeaways and FAQ blocks are also the structures AI search engines most readily extract — a point that returns in Part XIII.
Roughly 7 in 10 companies now run a centralised hub. Page-level fundamentals are largely in place — clear H2/H3 headings on more than 4 in 5 sites, and healthy linking.
Modern reading aids appear on only about half of sites. And most tellingly for an audience of clinicians, researchers and executives, only about 1 in 9 articles open with a "key takeaways" summary. In a sector whose readers are paid to skim for signal, that omission is friction dressed as rigour.
This dimension scores 2.34 out of 4 — a paradox of high competence and low translation.
What works
~9 in 10
Content-active companies demonstrate real scientific substance.
The regulatory vocabulary is fluent — FDA, HIPAA, clinical trials, GDPR and GxP, with EMA, ISO, IND, CE marking, CLIA and 21 CFR Part 11 all in regular rotation.
What's missing
~1 in 4
Companies map their technical content to the buyer's actual compliance journey.
Dedicated regulatory or compliance sections inside resource hubs are rare — fewer than 1 in 10 — even though "how do I stay compliant while doing X" is one of the highest-intent questions this buyer ever asks.
The translation gap
The content answers "what is it?" brilliantly and "how does it get me through the regulator?" almost never. The second question is the one with a budget attached.
Experience, Expertise, Authoritativeness and Trust is the strongest dimension at 2.72 out of 4 — no accident in an industry where credibility is a prerequisite for being read at all.
EEAT signal prevalence — share of content-active companies
Roughly 7 in 10 companies publish under named authors; close to 3 in 5 attach bios listing real credentials (MD, PhD, PharmD). About 7 in 10 feature original data and nearly two-thirds include peer-reviewed citations.
One easy win stands out by its absence. Formal editorial policies — a published statement of how content is reviewed for scientific and medical accuracy — appear on barely 1 in 30 sites. For an industry that already does the hard part, publishing the governance behind it is a near-free differentiator.
Two findings sit in tension. On positioning, the sector excels: ICP clarity scores 3.66 out of 4. But the public-facing proof that turns positioning into a closed deal is thin.
Positioning · 3.66/4
Nearly 9 in 10 companies communicate clearly who they serve and what problem they solve. Life sciences companies rarely hide behind generic messaging — their science forces specificity.
Sales enablement · 2.48/4
With case studies on only ~1 in 4 sites and ROI tooling all but absent, sales teams re-create proof in private — bespoke decks, one-off references — instead of letting a public library accelerate the deal before the first call.
The asymmetry
The positioning is ready for the market; the evidence layer behind it isn't.
Distribution is the lowest-scoring dimension across the entire study — 1.72 out of 4. The dominant mode is to host content on the website and hope the market finds it.
Active distribution
~1 in 11
Show strong signals of actively distributing or repurposing their content.
Newsletter
~33%
A third offer a newsletter; active webinar programs reach fewer than 1 in 5.
Freshness — the irony
3.34/4
~4 in 5 keep content updated. The sector diligently waters a garden almost no one is invited into.
The reframe
Distribution is a product, not an afterthought. One flagship asset should fan out into a landing page, segmented email, narrative social, partner placements and paid amplification — a planned set of touchpoints across weeks, not a single "we just published this" post.
Where life sciences companies do rank, the keyword mix exposes the same front-loaded funnel seen in the content itself.
Ranking-keyword mix by funnel intent
Example MOFU targets the sector under-serves: "best CRO for cell therapy," "comparing sequencing platforms," "CRO selection criteria."
Close to 7 in 10 ranking keywords are informational; another 1 in 5 are branded. The commercial-investigation middle captures barely 1 in 30 — the search equivalent of the missing case study.
The sector competes hard for general scientific interest, where it is up against Wikipedia and the NIH, and concedes the high-intent commercial queries where it would actually face few credible competitors. The whitespace isn't more TOFU; it's the buyer's-guide and platform-comparison content almost no one is writing.
Paid acquisition is strikingly underused. Only about 1 in 5.5 companies run Google Ads at all; LinkedIn reaches a little over 1 in 3.
LinkedIn ad objectives across life sciences advertisers
Nearly three-quarters of LinkedIn ad spend chases generic brand awareness — company milestones and platform announcements. Explicit lead generation accounts for barely 1 in 40 ads.
The competitive edge is plainly available: shift from "look at us" to gated thought leadership and lead-gen creative aimed at named roles — Chief Medical Officer, VP of Clinical Operations, Head of Regulatory — and you are bidding into a channel your competitors are using as a billboard.
This is the finding that should reframe the next two years of strategy. Run a set of non-branded industry queries through AI search, and the corporate sector is essentially invisible.
100%
Of tested industry queries triggered an AI Overview.
~0
Analysed companies surfaced in those AI answers (directional).
6
Sources dominate instead — Mayo Clinic, Cleveland Clinic, Wikipedia, NCBI/NIH, YouTube, CDC. None corporate.
The lesson of Generative Engine Optimisation (GEO) is uncomfortable but clear — your own blog, however good, is not the path into AI answers. Earned authority is. The companies that will appear in 2027's AI results are the ones investing now in digital PR, authoritative third-party placements, structured and extractable on-page content (those missing "key takeaways" and FAQ blocks from Part VI), and citation-worthy original data.
The single highest-leverage move
For most life sciences companies, the single highest-leverage content investment of 2026 is not another blog post. It is becoming the kind of source an AI engine is willing to cite.
Analytics adoption is high — most companies run basic tracking — but the marketing-automation and CRM layer that powers real nurture and ABM is thinly adopted. WordPress dominates the CMS landscape; sophisticated automation platforms are the exception.
Modelled monthly digital budget benchmarks, by company stage — directional
| Company stage | Est. monthly digital budget | Typical allocation |
|---|---|---|
| Early-stage (Seed / Series A) | $5k – $15k | ~60% content & SEO · ~40% LinkedIn ads |
| Growth-stage (Series B / C) | $25k – $75k | ~40% content · ~40% LinkedIn · ~20% Google |
| Late-stage (Series D+ / Public) | $100k – $500k+ | ~30% content · ~30% LinkedIn · ~30% Google · ~10% programmatic / ABM |
Modelled estimates — built from traffic value, CPC and ad-presence signals rather than disclosed budgets. Excludes headcount and event/conference spend. Use as a planning frame, not a quote.
Job postings are a leading indicator. Budgets follow headcount, and a job description encodes the operating model a team is trying to build.
Competencies requested across life sciences marketing roles
The most common single requirement across all postings is not a marketing skill at all. Scientific or therapeutic-area knowledge appears in roughly 7 in 10 roles — ahead of any channel or craft.
Data and analytics (~2 in 3) and regulatory/compliance (~half) have moved from back-office adjuncts into core marketing competencies. Meanwhile copywriting and design sit far lower, consistent with their being outsourced.
The hiring takeaway
An industry hiring scientists who can market →
Channels & tactics named in roles — relationship-led, not funnel-led
Percentages read as conservative floors: roughly a quarter of postings are non-English and keyword detection is multilingual-conservative, so true prevalence is likely somewhat higher.
Events, tradeshows and congresses are named in nearly half of postings — roughly five times more often than SEO or paid media.
Search and content are underexploited, not saturated: a 1-in-10 SEO signal and a 1-in-7 content signal across regulated, high-consideration categories is whitespace. The absence of ABM language is notable given how account-shaped life-science buying actually is — the function exists in practice as key-account and field marketing, but isn't yet labelled or tooled as ABM.
Fewer than 1 in 11 roles mention AI or machine learning, and under 1 in 30 mention generative AI. The stronger signal is automation and workflow (~1 in 5) — teams want operational efficiency more than frontier capability. AI mentions decline with company size, from ~13% in the smallest firms to ~7% in enterprises. In a world where every claim is governed by medical-legal-regulatory review, unconstrained generative output is a compliance liability — which is why the enterprise opportunity is governed AI: tools that accelerate MLR review, content versioning and compliant personalisation within guardrails.
The single clearest pattern in the demand-side data is that the larger the employer, the more its hiring tilts toward compliance, therapeutic-area depth and KOL/HCP engagement. The smaller the employer, the more it resembles conventional search-, content- and social-led demand generation.
| Dimension | Smaller (≤200 employees) | Larger (1,000+ employees) |
|---|---|---|
| Centre of gravity | Digital demand-gen: search, social, content, web | Science, compliance, KOL/HCP, events, field |
| Top skills | Generalist digital, content, social | Therapeutic depth, MLR/regulatory, analytics, orchestration |
| AI posture | More experimental (~13%) | More cautious (~7%), governance-bound |
| Team & budget | Lean; competes on benefits & flexibility | Senior in-house core; manager/director-led spend |
| Best entry motion | Evidence-led SEO/AEO, content, webinars | Proprietary data, congress presence, omnichannel, compliant AI |
The structural fact
Compliance requirements alone more than quadruple from the smallest to the largest firms. There are, in effect, two distinct marketing operating models hiding inside one industry label.
Content marketing maturity scales predictably with funding stage, but unevenly across dimensions.
Seed and early-stage companies over-index on credibility and technical depth — they establish authority first — while lacking the infrastructure for navigation or conversion.
Late-stage venture companies represent the peak across every dimension: they have both the resources to build proper hubs and the mandate to drive measurable pipeline.
Then comes the post-IPO retreat. Demand-capture scores for IPO-stage companies fall to around 1.64 out of 4, below the already-low sector mean. As corporate-comms oversight rises, the function drifts from lead generation toward brand maintenance.
The through-line of the whole report
Life sciences marketing is rich in credibility and craft and poor in conversion and distribution. It builds authority it never operationalises into pipeline.
The demand-side hiring signal confirms the cause: teams are built around science, compliance, events and relationships, with the conversion-and-distribution layer treated as a thin afterthought.
The implication for challengers is direct: the growth-stage window, before post-IPO conservatism sets in, is when content operations are both most capable and most willing to convert.
Every gap in this report is a competitor's omission you can claim. Five stand out — and none require out-spending the enterprise incumbents at congresses. They require operating the layer the incumbents under-invest in.
Case studies, comparison pages, ROI framing and buyer's guides are nearly absent — yet they're what high-intent buyers need to finalise procurement. Build the bottom of the funnel the sector skipped.
Content marketingFriction is already low; the missing piece is funnel-aware CTAs and a next step on every page. This is pipeline you capture without creating anything new.
Marketing automationThe sector concedes commercial-investigation queries to compete with Wikipedia on TOFU. Rank for 'best [category] for [use case]' and you face almost no one.
Inbound lead generationMaintenance is strong, distribution is weakest. Turning one flagship asset into a sequenced, multi-channel campaign compounds value the sector is leaving on the shelf.
Demand generationCorporate sites are being ignored by AI engines today. Earned authority, extractable structure and citation-worthy data are the path into the answers buyers will read in 2027.
Thought leadership RevOpsIn closing
The state of content marketing for life science companies in 2026 is one of profound, unevenly-distributed potential. The hard part — authority — is largely solved. The cheaper, higher-leverage part — connecting it to a buyer journey, distributing it as a product, and making it legible to search and AI — is wide open.
This report maps the industry. A Content RevOps audit maps you — scoring your content presence, conversion architecture, distribution and AI-search readiness against these benchmarks, and identifying the specific gaps between the authority you've built and the pipeline you're capturing.
About this report — produced by Content RevOps as a first-party industry diagnostic. Synthesises original analysis of roughly 2,000 life sciences companies (biotech, pharma, MedTech, diagnostics, CROs/CDMOs) and 1,000 marketing job postings, collected in H1 2026. Findings combine company-website audits, search and paid-media data, an AI-search visibility probe, and demand-side hiring analysis. Findings reported as proportions and ratios; thinner evidence is flagged inline as directional.